Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.
| Original language | English (US) |
|---|---|
| Article number | 1436 |
| Journal | F1000Research |
| Volume | 5 |
| DOIs | |
| State | Published - 2016 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
- Immunology and Microbiology(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Recent advances in understanding and treating vasculitis [version 1; referees : 2 approved]. / Koster, Matthew; Warrington, Kenneth J.
In: F1000Research, Vol. 5, 1436, 2016.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Recent advances in understanding and treating vasculitis [version 1; referees
T2 - 2 approved]
AU - Koster, Matthew
AU - Warrington, Kenneth J
PY - 2016
Y1 - 2016
N2 - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.
AB - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are near universally fatal conditions if untreated. Although effective therapeutic options are available for these diseases, treatment regimens are associated with both short- and long-term adverse effects. The recent identification of effective B-cell-targeted therapy with an anti-CD20 monoclonal antibody has transformed the treatment landscape of AAV. Questions, nevertheless, remain regarding the appropriate timing, dose, frequency, duration, and long-term effects of treatment. The aim of this article is to provide an overview of the current information, recent advances, ongoing clinical trials, and future treatment possibilities in AAV.
UR - http://www.scopus.com/inward/record.url?scp=85010991079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010991079&partnerID=8YFLogxK
U2 - 10.12688/F1000RESEARCH.8403.1
DO - 10.12688/F1000RESEARCH.8403.1
M3 - Review article
VL - 5
JO - F1000Research
JF - F1000Research
SN - 2046-1402
M1 - 1436
ER -